InvestSMART

Pathkey.AI Ltd (ASX:PKY)

ALERT: Price-sensitive ASX Announcement for PKY
Current share price for PKY : $0.039 0.014 (56%)+
Announcement
Release
9 Oct 2025 9:17AM
Price at Release
$0.025
Full Release
download
Summary
Pathkey.AI Ltd has released an update demonstrating the success of its TrialKey AI platform in predicting successful clinical trials. The platform, which analyses global clinical trial data, identified four new significant events in September 2025 that validated its ability to forecast trials with above-average success probabilities. TrialKey's predictive capabilities have led to a 43.6% average share price increase in observed programs from prediction to inflection. Eleven more programs are under monitoring, with an average return of 16.7% on these stocks pending clinical outcomes. The company collaborates with L39 Capital to apply TrialKey insights in their AI Biotech Fund. The report emphasizes the utility of TrialKey in clinical trial optimization, insurance, and biotech investing, while disclaiming investment advice. Pathkey.AI is dedicated to transforming drug development through AI-driven innovations.
Key Points
  • Four new inflection events observed in September 2025.
  • Average share price change of +43.6% for reported programs.
  • Eleven programs under monitoring for upcoming outcomes.
  • TrialKey insights applied in trial optimization, insurance, and biotech investing.
  • Partnership with L39 Capital for AI Biotech Fund.
  • TrialKey predicts trials with a success probability significantly better than baseline rates.
  • Observational reports are not trading recommendations or investment advice.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.